FI
Fosun International Portfolio holdings
AUM
$360M
1-Year Return
38.28%
This Quarter Return
-8.62%
1 Year Return
+38.28%
3 Year Return
+3.77%
5 Year Return
+27.59%
10 Year Return
+94.55%
AUM
$902M
AUM Growth
-$613M
(-40%)
Cap. Flow
-$410M
Cap. Flow
% of AUM
-45.44%
Top 10 Holdings %
Top 10 Hldgs %
57.67%
Holding
341
New
42
Increased
40
Reduced
54
Closed
114
Top Buys
| 1 |
Amneal Pharmaceuticals
AMRX
|
$5.71M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$2.78M |
| 3 |
Wheaton Precious Metals
WPM
|
$2.57M |
| 4 |
TSMC
TSM
|
$2.01M |
| 5 |
Booking.com
BKNG
|
$1.5M |
Top Sells
| 1 |
DigitalBridge
DBRG
|
$33.8M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
$23.1M |
| 3 |
Incyte
INCY
|
$10.1M |
| 4 |
Neurocrine Biosciences
NBIX
|
$9.75M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$9.33M |
Sector Composition
| 1 | Healthcare | 16.66% |
| 2 | Industrials | 5.91% |
| 3 | Financials | 5.49% |
| 4 | Technology | 5.04% |
| 5 | Communication Services | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLRX
226
BioLineRX
BLRX
$15.1M
| – | – |
-1,217
| Closed | -$263K |
|
227
Bristol-Myers Squibb
BMY
$95B
| – | – |
-83,000
| Closed | -$3.74M |
|
228
Cidara Therapeutics
CDTX
$1.65B
| – | – |
-15,334
| Closed | -$481K |
|
229
Cerus
CERS
$255M
| – | – |
-669,245
| Closed | -$3.31M |
|
230
Check Point Software Technologies
CHKP
$20.5B
| – | – |
-1,800
| Closed | -$207K |
|
231
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| – | – |
-238,248
| Closed | -$5.12M |
|
232
Costco
COST
$424B
| – | – |
-1,000
| Closed | -$266K |
|
233
Curis
CRIS
$21.4M
| – | – |
-29,092
| Closed | -$1.07M |
|
234
Corvus Pharmaceuticals
CRVS
$427M
| – | – |
-184,116
| Closed | -$624K |
|
235
CytomX Therapeutics
CTMX
$346M
| – | – |
-97,457
| Closed | -$1.04M |
|
236
Cytokinetics
CYTK
$5.95B
| – | – |
-148,353
| Closed | -$1.64M |
|
|
237
DigitalBridge
DBRG
$2.05B
| – | – |
-1,692,324
| Closed | -$33.8M |
|
238
Emerson Electric
EMR
$74.9B
| – | – |
-3,470
| Closed | -$229K |
|
239
Amicus Therapeutics
FOLD
$2.47B
| – | – |
-741,969
| Closed | -$8.9M |
|
240
Heron Therapeutics
HRTX
$202M
| – | – |
-171,557
| Closed | -$3.16M |
|
|
241
Incyte
INCY
$16.7B
| – | – |
-119,310
| Closed | -$10.1M |
|
|
242
Iovance Biotherapeutics
IOVA
$796M
| – | – |
-413,154
| Closed | -$9.33M |
|
243
Ironwood Pharmaceuticals
IRWD
$179M
| – | – |
-439,853
| Closed | -$4.76M |
|
244
KALA BIO
KALA
$102M
| – | – |
-4,925
| Closed | -$1.45M |
|
245
Kura Oncology
KURA
$706M
| – | – |
-370,958
| Closed | -$7.34M |
|
246
Lexicon Pharmaceuticals
LXRX
$389M
| – | – |
-181,000
| Closed | -$1.1M |
|
247
McKesson
MCK
$86B
| – | – |
-7,985
| Closed | -$1.07M |
|
248
MEI Pharma
MEIP
$140M
| – | – |
-19,826
| Closed | -$995K |
|
249
MacroGenics
MGNX
$123M
| – | – |
-131,573
| Closed | -$2.19M |
|
250
MSCI
MSCI
$43.1B
| – | – |
-875
| Closed | -$205K |
|